Genetic tumor syndromes are due to inherited genetic mutations, which have recently come to the attention of clinicians due to the widespread adoption of DNA sequencing, ultimately leading to imaging for surveillance. As a result, radiologists must be familiar with the clinical, genetic, and radiologic features of these syndromes. This article reviews genetic tumor syndromes of the head and neck according to the recently updated WHO’s 5th edition.
JiangHHeK. Statistics in the genomic era. Genes2020; 11: 443.
2.
WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): international agency for research on cancer. In: WHO classification of tumours series. 5th edn.2022, https://publications.iarc.fr/
3.
VijapuraCSaad AldinECapizzanoAA, et al.Genetic syndromes associated with central nervous system tumors. Radiographics2017; 37: 258–280.
4.
KimonisVEMehtaSGDigiovannaJJ, et al.Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med2004; 6: 495–502.
5.
LoMLNociniPFSavoiaA, et al.Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet1999; 55: 34–40.
6.
EvansDGLadusansEJRimmerS, et al.Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet1993; 30: 460–464.
7.
SartipKKaplanAObeidG, et al.Neuroimaging of nevoid basal cell carcinoma syndrome (NBCCS) in children. Pediatr Radiol2013; 43: 620–627.
MariaGArmandoCFrancescaB, et al. Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome—A New Clinical Perspective. Clin Cancer Res. 2009; 1157: 2463–2471. doi:10.1158/1078-0432.CCR-08-2023.
10.
ChoudryQPatelHCGurusingheNT, et al.Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Childs Nerv Syst2007; 23: 133–136.
11.
FriedmanNeurofibromatosisJM.1.1998 Oct 2 [Updated 2022 Apr 21]. In: AdamMPFeldmanJMirzaaGM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from:https://www.ncbi.nlm.nih.gov/books/NBK1109/
12.
GroverDSBKundraDRGroverDHGuptaDVGuptaDR. Imaging diagnosis of plexiform neurofibroma- unravelling the confounding features: A report of two cases. Radiol Case Rep. 2021; 1716(9): 2824-2833. doi: 10.1016/j.radcr.2021.06.025.
13.
DrSBGKundraDRGroverDH, et al.Imaging diagnosis of plexiform neurofibroma- unravelling the confounding features: a report of two cases. Radiol Case Rep2021; 16: 2824–2833.
14.
de BlankPMKFisherMJLiuGT, et al.Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc2017; 37: S23–S32.
15.
RussoCRussoCCasconeD, et al.Non-oncological neuroradiological manifestations in NF1 and their clinical implications. Cancers2021; 13: 1831.
LokCViseuxVAvrilMF, et al.Brain magnetic resonance imaging in patients with cowden syndrome. Medicine (Baltim)2005; 84: 129.
22.
JooGDoumanianJ. Radiographic findings of dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) in a woman with cowden syndrome: a case study and literature review. J Radiol Case Rep2020; 14: 1–6.
23.
NoséVLazarAJ. Update from the 5th edition of the world health organization classification of head and neck tumors: familial tumor syndromes. Head Neck Pathol2022; 16: 143–157.
24.
BennDERobinsonBGClifton-BlighRJ. 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1–5. Endocr Relat Cancer2015; 22: T91–T103.
25.
ThelenJBhattAA. Multimodality imaging of paragangliomas of the head and neck. Insights Imaging2019; 10: 29.
26.
LinEPChinBBFishbeinL, et al.Head and neck paragangliomas: an update on the molecular classification, state-of-the-art imaging, and management recommendations. Radiol Imaging Cancer2022; 4: e210088.
27.
OtaYNaganawaSKurokawaR, et al.Assessment of MR imaging and CT in differentiating hereditary and nonhereditary paragangliomas. AJNR Am J Neuroradiol2021; 42: 1320–1326.
28.
MathiesenJSEffraimidisGRossingM, et al.Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol2022; 79: 163–179.
29.
WellsSAAsaSLDralleH, et al.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc2015; 25: 567–610.
30.
ScarsbrookAFThakkerRVWassJAH, et al.Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics2006; 26: 433–451.
31.
KushchayevSVKushchayevaYSTellaSH, et al.Medullary thyroid carcinoma: an update on imaging. J Thyroid Res2019; 2019: 1893047.
32.
JhaSSimondsWF. Molecular and clinical spectrum of primary hyperparathyroidism. Endocr Rev2023; 44: 779–818.
33.
YamashitaYAkiyamaTMizusawaN, et al.A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int J Oral Maxillofac Surg2007; 36: 365–369.
34.
KhanMMFazliHKhanTB, et al.Hyperparathyroidism jaw-tumor syndrome: a case report from a radiological view. Cureus2022; 14. DOI: 10.7759/cureus.28329.
35.
NaganawaSDonohueTCapizzanoA, et al.Neuroradiology manifestations of Li-Fraumeni syndrome: epidemiology, genetics, imaging findings, and management. Neurographics2020; 10: 228–235.
36.
McBrideKABallingerMLKillickE, et al.Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol2014; 11: 260–271.
37.
BeckhamTHLeemanJJillian TsaiC, et al.Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: series of 9 cases and review of the literature. Head Neck2019; 41: 1418–1426.
38.
ScheckenbachKWagenmannMFreundM, et al.Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines. Klin Pädiatr2012; 224: 132–138.
39.
ZhangM-JCaoY-XWuH-Y, et al.Brain imaging features of children with Hoyeraal-Hreidarsson syndrome. Brain Behav2021; 11: e02079.
40.
FarinaLUggettiCOttoliniA, et al.Ataxia-telangiectasia: MR and CT findings. J Comput Assist Tomogr1994; 18: 724–727.
41.
AroraHChaconAHChoudharyS, et al.Bloom syndrome. Int J Dermatol2014; 53: 798–802.
42.
KarsdorpNEldersonAWittebol-PostD, et al.Von Hippel-Lindau disease: new strategies in early detection and treatment. Am J Med1994; 97: 158–168.
43.
CheadleJPReeveMPSampsonJR, et al.Molecular genetic advances in tuberous sclerosis. Hum Genet2000; 107: 97–114.
44.
LuDSKarasPJKruegerDAWeinerHL. Central nervous system manifestations of tuberous sclerosis complex. Am J Med Genet Part C. 2018; 178C: 291–298.
https://doi.org/10.1002/ajmg.c.31647
45.
WangMXSegaranNBhallaS, et al.Tuberous sclerosis: current update. Radiographics2021; 41: 1992–2010.
46.
AlshoabiSAHamidAMAlhazmiFH, et al.Diagnostic features of tuberous sclerosis complex: case report and literature review. Quant Imag Med Surg2022; 12: 84661–84861.
47.
GaillardA-LCrombéAJeckoV, et al.Magnetic resonance imaging diagnosis of subependymal giant cell astrocytomas in follow-up of children with tuberous sclerosis complex: should we always use contrast enhancement?Pediatr Radiol2020; 50: 1397–1408.
